- Prescribing of SGLT2 inhibitors increased substantially among people targeted by updated American diabetes guidance.
- Clinicians who later scored more highly on a professional knowledge assessment tended to show larger increases in guideline-concordant SGLT2 prescribing.
- The observational study cannot establish that better knowledge-test scores caused prescribing changes or that the findings apply directly to NHS practice.
Updating clinical guidelines does not necessarily mean every eligible patient immediately receives the treatments being recommended.
A new study published in JAMA Network Open has investigated how prescribing changed after American diabetes guidelines placed greater emphasis on medicines that can protect the heart and kidneys.
Researchers examined prescription records for 177,284 older adults with type 2 diabetes receiving care from 1,061 endocrinologists in the United States.
The analysis focused on changes following a 2019 American Diabetes Association guideline update.
It also explored whether prescribing patterns differed according to physicians’ later scores in a professional knowledge assessment. JAMA Network
What changed after the guidelines were updated?
The guidelines placed greater emphasis on using selected SGLT2 inhibitors and GLP-1 receptor agonists in people with particular cardiovascular or kidney-related conditions.
Researchers found that prescribing became more consistent with the guidance over time.
Between 2018 and 2022, the increase in adjusted SGLT2 inhibitor prescription-fill rates was 11.4 percentage points greater among patients targeted by the guidance than among those outside the targeted groups.
For GLP-1 receptor agonists, the corresponding difference was approximately 2.4 percentage points.
The findings indicate that prescribing changed after the guidance was updated, particularly for SGLT2 inhibitors.
However, they do not prove that the guideline revision alone caused the changes.
Other factors, including new evidence, medicine availability and reimbursement arrangements, were also changing during the period. JAMA Network
Did clinician knowledge make a difference?
The researchers compared prescribing trends with physicians’ scores on a subsequent professional knowledge assessment.
Doctors with higher scores tended to demonstrate larger increases in guideline-concordant SGLT2 inhibitor prescribing.
However, the study did not find the same statistically significant relationship for GLP-1 medicines.
There is also an important timing limitation.
The professional assessment scores were measured after the prescribing period.
That means the results cannot establish that achieving a higher score led to better prescribing.
The association may instead reflect broader differences in clinical practice, education or professional engagement.
Why does this matter for type 2 diabetes?
Diabetes treatment increasingly involves more than lowering HbA1c.
Certain medicines have demonstrated benefits for people with established cardiovascular disease, heart failure or chronic kidney disease.
For appropriate patients, these additional effects can influence which treatment is selected.
But the most suitable medicine still depends on individual health circumstances, contraindications, treatment preferences and access.
More prescriptions are not automatically better if medicines are given to people who are unlikely to benefit.
What is the UK angle?
The study used US Medicare data and American prescribing guidance.
Its findings cannot be treated as evidence that similar prescribing gaps exist within the NHS.
UK clinical decisions are informed by NICE recommendations, licensed indications and individual assessment.
Nevertheless, the research raises an important question for diabetes services: how effectively does new evidence translate into everyday clinical practice?
For people with type 2 diabetes, it reinforces the value of discussing cardiovascular and kidney health alongside glucose control during medication reviews.
The study highlights the challenges of implementing evidence-based treatment, rather than proving that any particular clinician or healthcare system is failing.






